BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court
路透社2026/10/07 13:31October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)
October 7 - ** Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24
** Halozyme stated it has obtained an injunction (link) from a Dutch court prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets
** The court ruled that Merck infringed Halozyme's EP622 patent and rejected Merck's claim that the patent was invalid
** Halozyme noted that patients can still access the intravenous form of Keytruda, which is not affected by the injunction
** As of the close of the previous trading session, HALO is up 62% year-to-date
(To assist non-native English speakers, Reuters provides automated translations of its reports in several other languages. Automated translation may contain errors or lack the necessary context; Reuters does not guarantee the accuracy of automated translation and provides it solely for the convenience of readers. Reuters assumes no responsibility for any harm or losses arising from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
American Express Stock Shocks Despite Positive Revenue and Earnings
The AI arms race extends upstream! Reports say Intel, Nvidia, and AMD are prepaying over 100 billions NTD to secure advanced IC substrate production capacity.
NVIDIA, Intel, and AMD have collectively spent $5 billion in advance payments to aggressively secure high-end IC substrates from Taiwan. Driven by "big money for guaranteed orders," the top three Taiwanese substrate manufacturers have invested a record NT$161.2 billion to expand their production capacity. The tech giants' substantial financial commitments to secure supply chains highlight the intense competition and extreme scarcity of core AI materials.
Crypto prices
More
